{
  "id": "mhgap#risk_safety_05da016b",
  "content": "Strength of recommendation: Conditional\nCertainty of evidence: Moderate\nJustification to produce these side-effects differed between\ny Evidence was extracted from three systematic the agents, but the differences were overall less\nreviews: Ceraso et al., 2020 (75 RCTs on antipsychotic pronounced than the efficacy differences.\nmedicines in schizophrenia) (191); Leucht et al.,\nRemarks\n2017 (167 RCTs on antipsychotic medicines in\ny The medicines included in the recommendation\nschizophrenia) (192); and Schneider-Thoma et al.,\ncorrespond to the WHO EML (13) and are listed in\n2018 (596 RCTs on second-generation antipsychotic\nalphabetical order.\nmedicines in individuals with severe mental\nillness) (193). y Clozapine should be offered for treatment-resistant\npsychosis, defined as psychosis that has not shown\ny Antipsychotics showed moderate effects for overall\nimprovement after receiving treatment from two\nefficacy (low-certainty evidence) and large effects\nalternative antipsychotics with adequate dose and\nfor prevention of relapse (high-certainty evidence).\ntime. Clozapine should only be offered where lab\nDifferences in efficacy between medicines were\ntests are available to monitor white blood cell count,\neither small or uncertain.\nand under a mental health specialist supervision.\ny Overall, for the medicines with data available, social\ny Evidence regarding the safety and effectiveness\nfunctioning (moderate-certainty evidence) and",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "risk_safety",
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General â€” Risk Safety Strength of recommendation: Conditional\nCertainty of evidence: Moderate\nJustification to produce these side-effects differed between\ny Evidence was extracted from three systematic the agents, but the differences were overall less\nreviews: Ceraso et al., 2020 (75 RCTs on antipsychotic pronounced than the efficacy differences.\nmedicines in schizophrenia) (191); Leucht et al.,\nRemarks\n2017 (167 RCTs on antipsychotic medicines in\ny The medicines included in the recommendation\nschizophrenia) (192); and Schneider-Thoma et al.,\ncorrespond to the WHO EML (13) and are listed in\n2018 (596 RCTs on second-generation antipsychotic\nalphabetical order.\nmedicines in individuals with severe mental\nillness) (193). y Clozapine should be offered for treatment-resistant\npsychosis, defined as psychosis that has not shown\ny Antipsychotics showed moderate effects for overall\nimprovement after receiving treatment from two\nefficacy (low-certainty evidence) and large effects\nalternative antipsychotics with adequate dose and\nfor prevention of relapse (high-certainty evidence).\ntime. Clozapine should only be offered where lab\nDifferences in efficacy between medicines were\ntests are available to monitor white blood cell count,\neither small or uncertain.\nand under a mental health specialist supervision.\ny Overall, for the medicines with data available, social\ny Evidence regarding the safety and effectiveness\nfunctioning (moderate-certainty evidence) and Strength of recommendation: conditional\ncertainty of evidence: moderate\njustification to produce these side-effects differed between\ny evidence was extracted from three systematic the agents, but the differences were ove..."
}